Axona helps patients with mild to moderate Alzheimer’s disease by addressing diminished cerebral glucose metabolism⁴

Extensive evidence from three decades of research has established that diminished cerebral glucose metabolism (DCGM, also known as glucose hypometabolism) is a key underlying pathology in the Alzheimer’s brain.¹ This leaves neurons less able to utilize glucose for fuel, leading to an energy shortage in the brain.¹ DCGM occurs early in the disease and correlates with symptoms and disease progression.^5-9

Axona helps address this deficiency by providing ketone bodies as an alternative fuel source for neurons.^3,4 Axona is the only available prescription medical food that addresses DCGM.^2,4 Adding Axona to Alzheimer’s disease management addresses different aspects of the disease at the same time and may further enhance memory and cognition.*⁴

Add Axona. Add what's been missing from Alzheimer's therapy.

Axona is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease.

Diminished cerebral glucose metabolism in Alzheimer’s disease^5,6

Find out more about one of the earliest brain changes that occurs in Alzheimer’s disease.

Ketone bodies: the brain’s natural back-up fuel^1,4

Find out how Axona can help during times of DCGM.

Read Accera's response to the recent FDA warning letter.